The PROSPECT II study was published in the March 13th issue of The Lancet,
finding that IVUS+NIRS imaging can detect plaques at increased risk for future adverse cardiac outcomes.VIEW ARTICLE VIEW ARTICLE

Resources

All of the trademarks, service marks, and logos displayed on the Infraredx, a Nipro Company are registered and unregistered trademarks of Infraredx, a Nipro Company and its affiliates. All Nipro Company and OKAY® II product images and logos are copyrighted and belong to NIPRO Corporation. Click here to view our terms of use.

Filters:

Products

Makoto™ Intravascular Imaging System

Brand Style Guide

View

Makoto™ Logos

Makoto™ System Product Photography

View

Dualpro™ Logos

IVUS + NIRS Catheter Product Photography

View

IVUS + NIRS Logos

The Heart Is Everything

Makoto™ Intravascular Imaging System Product Brochure

View

NIRS Chemogram Product Insert

View
OKAY® II Y-Connector

OKAY® II Logos

View

OKAY® II Product Photography

View

OKAY II Comparison Time Lapse from Infraredx, a Nipro Company on Vimeo.

OKAY® II Y-Connector Time Lapse Video

Time lapse footage demonstrating a Leak Test between the OKAY II Y-Connector and two competitor devices over a 3-minute period.

OKAY® II Product Information Sheet

View
GM-30 Inflation Device

GM-30 Inflation Device Product Information Sheet

View

Clinical Education

Education

EuroPCR 2021

Dr. Giulio Guagliumi and Dr. Tina Vilsbøll discuss how intravascular imaging can enhance the continuum of care.

EuroPCR 2020 e-Course

featuring Dr. Giulio Guagliumi discussing the "Use of IVUS + NIRS imaging for decision making in Acute Coronary Syndrome."

Prospect II: A Prospective Natural History Study

Prospect II: A Prospective Natural History Study Using NIRS-IVUS Imaging in Patients with Acute Myocardial Infarction

Webinar: Clinical Innovations in IVUS NIRS Imaging

The first installment of the Infraredx, a Nipro Company, webinar series features Dr. Giulio Guagliumi of Ospedale Papa Giovanni XXIII in Bergamo, Italy, discussing "Clinical Innovations in IVUS+NIRS Imaging."

Part I: Presented by David Erlinge, MD

Identification of Vulnerable Plaque: From PROSPECT to LRP and PROSPECT II

Part II: Presented by Lorenz Räber, MD

Pharmacologic Treatment of Vulnerable Plaque: Background and the PACMAN AMI Study

Part III: Presented by Gregg Stone, MD

Interventional Treatment of Vulnerable Plaque: Insights from PROSPECT ABSORB

Part IV: Panel Discussion

Corporate

Infraredx™, a Nipro Company

Infraredx Brand Style Guidelines

View

Infraredx™, a Nipro Company Logos

© 2020 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative